Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor

British Journal of Clinical Pharmacology

Volumn 81, Issue 5, 2016, Pages 971-979

  Lazaar, Aili L ^a   Yang, Lucy ^b   Boardley, Rebecca L ^c   Goyal, Navin S ^a   Robertson, Jonathan ^c   Baldwin, Sandra J ^c   Newby, David E ^e   Wilkinson, Ian B ^b   Tal Singer, Ruth ^a   Mayer, Ruth J ^a   Cheriyan, Joseph ^b,c,d  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

clinical pharmacology; clinical trial; COPD; smoking; soluble epoxide hydrolase

Indexed keywords

BIOLOGICAL MARKER; DRUG METABOLITE; ENZYME INHIBITOR; FIBRINOGEN; GSK 2256294; PLACEBO; UNCLASSIFIED DRUG; VASCULOTROPIN; CYCLOHEXYLAMINE DERIVATIVE; DIHOMO GAMMA LINOLENIC ACID; EPHX2 PROTEIN, HUMAN; EPOXIDE HYDROLASE; N-((4-CYANO-2-(TRIFLUOROMETHYL)PHENYL)METHYL)-3-((4-METHYL-6-(METHYLAMINO)-1,3,5-TRIAZIN-2-YL)AMINO)CYCLOHEXANECARBOXAMIDE; TRIAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FIBRINOGEN BLOOD LEVEL; FOOD; HEADACHE; HUMAN; MALE; OBESITY; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SMOKING; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; DERMATITIS, CONTACT; HALF LIFE TIME; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

8,11,14-EICOSATRIENOIC ACID; ADOLESCENT; ADULT; AGED; COHORT STUDIES; CROSS-OVER STUDIES; CYCLOHEXYLAMINES; DERMATITIS, CONTACT; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EPOXIDE HYDROLASES; FEMALE; HALF-LIFE; HEADACHE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; OBESITY; TRIAZINES; YOUNG ADULT;

EID: 84958025570     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12855     Document Type: Article

References (41)

1. Morisseau C, Hammock BD,. Impact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health. Annu Rev Pharmacol Toxicol 2012; 12: 37-58.
2. Zhang G, Kodani S, Hammock BD,. Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Prog Lipid Res 2014; 53: 108-23.
3. Spector AA, Norris AW,. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007; 292: C996-1012.
4. Bellien J, Joannides R, Richard V, Thuillez C,. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? Pharmacol Ther 2011; 131: 1-17.
5. Imig JD, Hammock BD,. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009; 8: 794-805.
6. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK,. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276-9.
7. Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW, Zeldin DC,. Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther 2003; 307: 753-64.
8. Abraham NG, Sodhi K, Silvis AM, Vanella L, Favero G, Rezzani R, Lee C, Zeldin DC, Schwartzman ML,. CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype. Hypertension 2014; 64: 1352-61.
9. Duflot T, Roche C, Lamoureux F, Guerrot D, Bellien J,. Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases. Expert Opin Drug Discov 2014; 9: 229-43.
10. Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM,. Epoxyeicosatrienoic acids and cardioprotection: The road to translation. J Mol Cell Cardiol 2014; 74: 199-208.
11. Zheng J, Plopper CG, Lakritz J, Storms DH, Hammock BD,. Leukotoxin-diol: a putative toxic mediator involved in acute respiratory distress syndrome. Am J Respir Cell Mol Biol 2001; 25: 434-8.
12. Yang J, Bratt J, Franzi L, Liu J-Y, Zhang G, Zeki A, Voge CF, Williams K, Dong H, Lin Y, Hwang SH, Kenyon NJ, Hammock BD,. Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice. Am J Respir Cell Mol Biol 2015; 52: 46-55.
13. Wang L, Yang J, Guo L, Uyeminami D, Dong H, Hammock BD, Pinkerton KE,. Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2012; 46: 614-22.
14. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD,. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A 2005; 102: 2186-91.
15. Norton SK, Wijesinghe DS, Dellinger A, Sturgill J, Zhou Z, Barbour S, Chalfant C, Conrad DH, Kepley CL,. Epoxyeicosatrienoic acids are involved in the C 70 fullerene derivative-induced control of allergic asthma. J Allergy Clin Immunol 2012; 130: 761-9.
16. Zhou Y, Sun G-Y, Liu T, Duan J-X, Zhou H-F, Lee KS, Hammock BD, Fang X, Jiang J-X, Guan C-X,. Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice. Cell Tissue Res 2015. doi: 10.1007/s00441-015-2262-0 Available from: http://link.springer.com/10.1007/s00441-015-2262-0
17. Ono E, Dutile S, Kazani S, Wechsler ME, Yang J, Hammock BD, Douda DH, Tabet Y, Khaddaj-Mallat R, Sirois M, Sirois C, Rizcallah E, Rousseau E, Martin R, Sutherland ER, Castro M, Jarjour N, Israel E, Levy BD,. Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med 2014; 190: 886-97.
18. Anandan SK, Webb HK, Chen D, Wang YX, Aavula BR, Cases S, Cheng Y, Do Zung N, Mehra U, Tran V,. 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorg Med Chem Lett 2011; 21: 983-8.
19. Chen D, Whitcomb R, MacIntyre E, Tran V, Do ZN, Sabry J, Patel DV, Anandan SK, Gless R, Webb HK,. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects. J Clin Pharmacol 2012; 52: 319-28.
20. Podolin PL, Bolognese BJ, Foley JF, Long E, Peck B, Umbrecht S, Zhang X, Zhu P, Schwartz B, Xie W, Quinn C, Qi H, Sweitzer S, Chen S, Galop M, Ding Y, Belyanskaya SL, Israel DI, Morgan BA, Behm DJ, Marino JP, Kurali E, Barnette MS, Mayer RJ, Booth-Genthe CL, Callahan JF,. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat 2013; 104-105: 25-31.
21. Lazaar AL, Yang L, Robertson J, Goyal N, Boardley R, Tal-Singer R, Cheriyan J, Newby D, Wilkinson I, Mayer RJ,. Safety and pharmacology of a soluble epoxide hydrolase inhibitor. Eur Res Soc 2015; 46: (Suppl. 59) DOI: 10.1183/13993003.congress-2015.PA2120.
22. Bloomer JC, Nash M, Webb A, Miller BE, Lazaar AL, Beaumont C, Guiney WJ,. Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling. Br J Clin Pharmacol 2013; 75: 488-96.
23. Webler AC, Michaelis UR, Popp R, Barbosa-Sicard E, Murugan A, Falck JR, Fisslthaler B, Fleming I,. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am J Physiol Cell Physiol 2008; 295: C1292-301.
24. Yang S, Wei S, Pozzi A, Capdevila JH,. The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Arch Biochem Biophys 2009; 489: 82-91.
25. Keserü B, Barbosa-Sicard E, Schermuly RT, Tanaka H, Hammock BD, Weissmann N, Fisslthaler B, Fleming I,. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovasc Res 2010; 85: 232-40.
26. Moghaddam MF, Grant DF, Cheek JM, Greene JF, Williamson KC, Hammock BD,. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med 1997; 3: 562-6.
27. Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer RC, Steimer J-L,. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 2004; 58: 618-31.
28. Zhao X, Dey A, Romanko OP, Stepp DW, Wang M-H, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD,. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2005; 288: R188-96.
29. Wei Q, Doris PA, Pollizotto MV, Boerwinkle E, Jacobs DR, Siscovick DS, Fornage M,. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 2007; 190: 26-34.
30. Jacobsen FK, Christensen CK, Mogensen CE, Andreasen F, Heilskov NS,. Postprandial serum creatinine increase in normal subjects after eating cooked meat. Proc Eur Dial Transplant Assoc 1979; 16: 506-12.
31. Medhora M, Dhanasekaran A, Gruenloh SK, Dunn LK, Gabrilovich M, Falck JR, Harder DR, Jacobs ER, Pratt PF,. Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat 2007; 1-4: 19-29.
32. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, Falck JR, Capdevila JH,. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 2005; 280: 27138-46.
33. Fleming I,. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 2007; 82: 60-7.
34. Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J, Edin ML, Lee CR, Benny O, Mudge DK, Butterfield CE, Mammoto A, Mammoto T, Inceoglu B, Jenkins RL, Simpson MA, Akino T, Lih FB, Tomer KB, Ingber DE, Hammock BD, Falck JR, Manthati VL, Kaipainen A, D'Amore PA, Puder M, Zeldin DC, Kieran MW,. Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci USA 2013; 110: 13528-33.
35. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio J, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, Zeldin DC,. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 2012; 122: 178-91.
36. Zhang G, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu J-Y, Wang Y, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW, Hammock BD,. Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci 2014; 111: 11127-32.
37. Janssen WJ, Yunt ZX, Muldrow A, Kearns MT, Kloepfer A, Barthel L, Bratton DL, Bowler RP, Henson PM,. Circulating hematopoietic progenitor cells are decreased in COPD. COPD 2014; 11: 277-89.
38. Taraseviciene-Stewart L, Voelkel NF,. Molecular pathogenesis of emphysema. J Clin Invest 2008; 394-402.
39. Zhen G, Xue Z, Zhao J, Gu N, Tang Z, Xu Y, Zhang Z,. Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. Cytotherapy 2010; 12: 605-14.
40. Tang K, Rossiter HB, Wagner PD, Breen EC,. Lung-targeted VEGF inactivation leads to an emphysema phenotype in mice. J Appl Physiol 2004; 97: 1559-66.
41. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF,. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000; 106: 1311-9.